---
id: nccn-hcc-2025
title: "NCCN Clinical Practice Guidelines in Oncology: Hepatocellular Carcinoma"
short_title: "Hepatocellular Carcinoma"
organization: National Comprehensive Cancer Network
country: United States
url: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1438
specialty: oncology
guideline_type: clinical-practice
evidence_system: nccn
conditions:
  - Hepatocellular Carcinoma
  - HCC
  - Liver Cancer
tags:
  - HCC
  - liver cancer
  - hepatocellular carcinoma
  - immunotherapy
  - TACE
publication_date: 2025-01-10
previous_version_date: 2024-01-15
status: current
supersedes: nccn-hcc-2024
superseded_by: null
pdf_path: null
has_pdf: false
last_reviewed: 2025-01-01
---

## Scope

This guideline provides recommendations for the diagnosis, staging, and treatment of hepatocellular carcinoma.

## Key Recommendations

### Surveillance
- At-risk populations (cirrhosis, chronic HBV): Ultrasound ± AFP every 6 months
- Consider CT/MRI if US suboptimal

### Diagnosis
- Imaging (LI-RADS criteria on CT/MRI) can be diagnostic
- Biopsy if imaging inconclusive
- AFP, AFP-L3, DCP as tumor markers

### Staging
- BCLC staging system guides treatment
- Assess liver function (Child-Pugh), performance status, tumor burden

### Potentially Curable (Very Early/Early Stage)
**Surgical Resection:**
- Single tumor, preserved liver function, no portal hypertension
- 5-year survival 50-70%

**Liver Transplantation:**
- Within Milan criteria (single ≤5cm or ≤3 tumors ≤3cm each)
- MELD exception points
- Bridge therapy while awaiting

**Ablation:**
- RFA, microwave ablation for tumors ≤3cm
- Alternative to surgery in early disease

### Intermediate Stage (BCLC B)
- TACE (transarterial chemoembolization)
- TARE (Y-90 radioembolization)
- Consider systemic therapy if poor TACE candidate

### Advanced Stage (BCLC C)
**First-Line Systemic Therapy:**
- Atezolizumab + bevacizumab (preferred)
- Durvalumab + tremelimumab (STRIDE regimen)
- Sorafenib, lenvatinib (if immunotherapy contraindicated)

**Second-Line:**
- Regorafenib (after sorafenib)
- Cabozantinib
- Ramucirumab (AFP ≥400)
- Pembrolizumab

### Child-Pugh B/C
- Supportive care primary focus
- Systemic therapy less well-tolerated
- Clinical trial if appropriate
